RecruitingB-cell Acute Lymphoblastic LeukemiaB-cell Non Hodgkin Lymphoma
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Eligible age
0–30 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.
Sponsor: University of Colorado, Denver
You may qualify if…
- ✓ Meets clinical criteria for leukapheresis or has a leukapheresis product previously collected and stored per recommended guidelines.
- ✓ Provision of signed and dated consent form from parent or guardian (patients \<18), the patient themselves (\>18), or legally authorized representative (patient \>18 who lack decision-making capacity); Pediatric patients will be included in age-appropriate discussions and assent will be obtained for those \> 7 years of age, when appropriate, according to institutional standards.
- ✓ Willingness to participate in long term follow up study.
- ✓ Stated willingness to comply with all study procedures and be available for the duration of the study.
- ✓ Males OR non-pregnant, non-breastfeeding females.
- ✓ o Patients of child-bearing potential or capable of fathering a child must agree to use highly effective contraception from the time of initial CAR T cell administration though 12 months following the final administration of investigational product.
- ✓ Aged 31 days to 30 years (inclusive) at time of consent and enrollment.
- ✓ Acute Lymphoblastic Leukemia (ALL) OR Non-Hodgkin Lymphoma (NHL) of B-cell origin that:
You may not qualify if…
- ✕ Evidence of rapidly progressive disease without adequate salvage/bridging regimens as determined by the investigator.
- ✕ Active Graft-versus-Host Disease (GvHD).
- ✕ Active, uncontrolled, life-threatening infection that at the determination of the treating physician would preclude safe leukapheresis or tolerance of LD chemotherapy, cell infusion, or cytokine release syndrome.
- ✕ Evidence of severe organ dysfunction as defined by:
- ✕ Myocardial dysfunction: Ejection fraction ≤ 40% or shortening fraction ≤ 28%, evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and clinically significant electrocardiogram (ECG) findings.
- ✕ Baseline oxygen saturation of ≤ 90% on room air
- ✕ Transaminases \> 10x upper limit of normal (ULN) or bilirubin \>2x the ULN, unless thought to be related to primary disease
- ✕ Estimated Cr clearance \<60 mL/min/1.73 m2 (if nuclear medicine GFR or other more specific testing exceeds this level than it can supersede the estimated clearance)
Where it's recruiting
Colorado
Aurora
Source: ClinicalTrials.gov · NCT04544592 · last updated 2026-09-14